Taxanes in the Treatment of Advanced Gastric Cancer

被引：17
作者：
Kang, Byung Woog [1 ]
Kwon, Oh-Kyoung [2 ]
Chung, Ho Young [2 ]
Yu, Wansik [2 ]
Kim, Jong Gwang [1 ]
机构：
[1] Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr, Sch Med,Canc Res Inst, 807 Hogukno, Daegu 41404, South Korea
[2] Kyungpook Natl Univ, Dept Surg, Kyungpook Natl Univ Hosp, Sch Med, Daegu 41494, South Korea
来源：
MOLECULES | 2016年 / 21卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
gastric cancer; taxanes; paclitaxel; docetaxel; chemotherapy; PHASE-III TRIAL; ALBUMIN-BOUND PACLITAXEL; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; PLUS CISPLATIN; ANTITUMOR-ACTIVITY; OPEN-LABEL; FLUOROURACIL; DOCETAXEL; ADENOCARCINOMA;
D O I：
10.3390/molecules21050651
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world. Taxanes (paclitaxel and docetaxel) are microtubule stabilizing agents that inhibit the process of cell division, and have shown antitumor activity in the treatment of AGC as a single or combination chemotherapy. Accordingly, this review focuses on the efficacy and tolerability of taxanes in the first-or second-line chemotherapy setting for AGC.
引用
收藏
页数：10
相关论文
共 50 条
[1]   Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action [J].
Abal, M. ;
Andreu, J. M. ;
Barasoain, I. .
CURRENT CANCER DRUG TARGETS, 2003, 3 (03) :193-203
[2]  
Ajani JA, 1998, CANCER J SCI AM, V4, P269
[3]   Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group [J].
Ajani, Jaffer A. ;
Moiseyenko, Vladimir M. ;
Tjulandin, Sergei ;
Majlis, Alejandro ;
Constenla, Manuel ;
Boni, Corrado ;
Rodrigues, Adriano ;
Fodor, Miguel ;
Chao, Yee ;
Voznyi, Edouard ;
Awad, Lucile ;
Van Cutsem, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3210-3216
[4]   Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group [J].
Ajani, Jaffer A. ;
Moiseyenko, Vladimir M. ;
Tjulandin, Sergei ;
Majlis, Alejandro ;
Constenla, Manuel ;
Boni, Corrado ;
Rodrigues, Adriano ;
Fodor, Miguel ;
Chao, Yee ;
Voznyi, Edouard ;
Marabotti, Cindy ;
Van Cutsem, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3205-3209
[5]  
Bang YJ, 2010, LANCET, V376, P1302
[6]   Chemotherapy for metastatic gastric cancer in Japan [J].
Boku, Narikazu .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (06) :483-487
[7]   Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803 [J].
Bouche, O ;
Raoul, JL ;
Bonnetain, F ;
Giovannini, M ;
Etienne, PL ;
Lledo, G ;
Arsène, D ;
Paitel, JF ;
Guérin-Meyer, V ;
Mitry, E ;
Buecher, B ;
Kaminsky, MC ;
Seitz, JF ;
Rougier, P ;
Bedenne, L ;
Milan, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4319-4328
[8]   A COMPARISON OF 3 CHEMOTHERAPEUTIC REGIMENS IN THE TREATMENT OF ADVANCED PANCREATIC AND GASTRIC-CARCINOMA - FLUOROURACIL VS FLUOROURACIL AND DOXORUBICIN VS FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN [J].
CULLINAN, SA ;
MOERTEL, CG ;
FLEMING, TR ;
RUBIN, JR ;
KROOK, JE ;
EVERSON, LK ;
WINDSCHITL, HE ;
TWITO, DI ;
MARSCHKE, RF ;
FOLEY, JF ;
PFEIFLE, DM ;
BARLOW, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 253 (14) :2061-2067
[9]   Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].
Cunningham, David ;
Starling, Naureen ;
Rao, Sheela ;
Iveson, Timothy ;
Nicolson, Marianne ;
Coxon, Fareeda ;
Middleton, Gary ;
Daniel, Francis ;
Oates, Jacqueline ;
Norman, Andrew Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46
[10]   Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel [J].
Desai, N ;
Trieu, V ;
Yao, ZW ;
Louie, L ;
Ci, S ;
Yang, A ;
Tao, CL ;
De, T ;
Beals, B ;
Dykes, D ;
Noker, P ;
Yao, R ;
Labao, E ;
Hawkins, M ;
Soon-Shiong, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1317-1324
12345